Figure 1: Pharmaceutical Market, US, Revenue ($B), 2011–2019
Figure 2: Medical Devices Market, US, Revenue ($B), 2015–2020
Figure 3: Healthcare Start-ups in the US, 2020
Figure 4: Country Profile, US, 2020
Figure 5: Pharmaceutical Market, US, Revenue ($B), 2011–2019
Figure 6: Pharmaceutical Market, US, Revenue Forecast ($B), 2020–2025
Figure 7: Novel Drug Approvals (Number), US, 2011–2021
Figure 8: Pharmaceutical Exports ($B), US, 2010–2019
Figure 9: Top Export Partners, US, 2019
Figure 10: Pharmaceutical Imports ($B), US, 2010–2019
Figure 11: Top Import Partners, US, 2019
Figure 12: Pharmaceutical Supply Channel Breakdown, US, 2019
Figure 13: Pharmaceutical Supply Channel Flow of Funds and Drugs, US, 2019
Figure 14: Annual Savings from Generic Drugs ($B), US, 2010–2019
Figure 15: Savings by Patient Condition ($B), US, 2019
Figure 16: Major Generic Drug Launches, US, 2020
Figure 17: Generic Drug Approvals, US, 2016–2020
Figure 18: Number of Biosimilars Approved, US, 2015–2020
Figure 19: Major Biosimilars Approval and Launch Dates, US, 2015–2020
Figure 20: OTC Medicines Market, Major Categories ($B), US, 2019
Figure 21: OTC Medicines Market, Revenue ($B), US, 2013–2020
Figure 22: OTC Medicines Market, Major Distribution Channels ($B), US, 2017
Figure 23: Total Expenditure by Therapeutic Class ($B), US, 2018
Figure 24: Major Therapeutic Areas by Household Consumption (million units), US, 2016–2018
Figure 25: COVID-19 (Number of cases), US, 2020–2021
Figure 26: COVID-19 (Number of deaths), US, 2020–2021
Figure 27: COVID-19 Fiscal Stimulus Timeline, US, 2020–2021
Figure 28: Goals of the Biden-Harris Plan to Beat COVID-19, US, 2021
Figure 29: COVID-19 Vaccine Distribution Process, US, 2020–2021
Figure 30: COVID-19 Vaccine Administration, Number of People, US, 2020–2021
Figure 31: Total Vaccine Administration by Type, US, 2020–2021
Figure 32: Top COVID-19 Healthcare IT Products by Application (Number of available marketed products), US, 2020–2021
Figure 33: Top COVID-19 Healthcare IT Products by Type (Number of available marketed products), US, 2020–2021
Figure 34: Top COVID-19 In Vitro Diagnostic (IVD) Products by Type (Number of available marketed products), US, 2020–2021
Figure 35: Top COVID-19 IVD Products by Manufacturer (Number of available marketed products), US, 2020–2021
Figure 36: Top COVID-19 IVD Products by Application (Number of available marketed products), US, 2020–2021
Figure 37: Top COVID-19 IVD Products by Device Class (Number of available marketed products), US, 2020–2021
Figure 38: COVID-19 Clinical Trials Count by Phase, US, 2020–2021
Figure 39: COVID-19 Clinical Trials Count by Trial Status, US, 2020–2021
Figure 40: Top Five COVID-19 Clinical Trials Sponsors by Count, US, 2020–2021
Figure 41: Pharmaceutical Market, Major Players, 2020
Figure 42: Medical Devices Market, US, Revenue ($B), 2015–2020
Figure 43: Medical Devices Market, US, Revenue Forecast ($B), 2021–2025
Figure 44: Medical Devices Market, Major Segments (%), US, 2020
Figure 45: Orthopedic Devices Market, US, Revenue ($B), 2017–2025
Figure 46: Orthopedic Devices Market, US, Market Share of Major Players (%), 2019
Figure 47: General Surgery Devices Market, US, Revenue ($B), 2017–2025
Figure 48: General Surgery Devices Market, US, Market Share of Major Players (%), 2019
Figure 49: Cardiovascular Devices Market, US, Revenue ($B), 2017–2025
Figure 50: Cardiovascular Devices Market, US, Market Share of Major Players (%), 2019
Figure 51: Healthcare IT Market, US, Revenue ($B), 2017–2025
Figure 52: Healthcare IT Market, US, Market Share of Major Players (%), 2017
Figure 53: Wound Care Management Market, US, Revenue ($B), 2017–2025
Figure 54: Wound Care Management Market, US, Market Share of Major Players (%), 2019
Figure 55: Diagnostic Market, US, Revenue ($B), 2015–2020
Figure 56: Diagnostic Market, US, Revenue ($B), 2021–2025
Figure 57: Medical Devices Market, US, Revenue ($B) of Major Companies, 2019
Figure 58: Deal Value and Deal Count, Pharmaceutical Market, US, 2020–2021
Figure 59: Deal Value and Deal Count, Quarterly, Pharmaceutical Market, US, 2020–2021
Figure 60: Deal Value and Deal Count Sub-types, Pharmaceutical Market, US, 2020–2021
Figure 61: Top Therapy Areas by Deal Value ($B), Pharmaceutical Market, US, 2020–2021
Figure 62: Top Therapy Areas by Deal Count, Pharmaceutical Market, US, 2020–2021
Figure 63: M&A Deals by Quarter, Pharmaceutical Market, US, 2020–2021 (by value and by number)
Figure 64: VC Deals by Quarter, Pharmaceutical Market, US, 2020–2021 (by value and by number)
Figure 65: Deal Value and Deal Count, Medical Devices Market, US, 2020–2021
Figure 66: Deal Value and Deal Count, Quarterly, Medical Devices Market, US, 2020–2021
Figure 67: Deal Value and Deal Count Sub-types, Medical Devices Market, US, 2020–2021
Figure 68: Top Equipment Areas by Deal Value ($B), Medical Devices Market, US, 2020–2021
Figure 69: Top Equipment Areas by Deal Count, Medical Devices Market, US, 2020–2021
Figure 70: M&A Deals by Quarter, Medical Devices Market, US, 2020–2021 (by value and by number)
Figure 71: VC Deals by Quarter, Medical Devices Market, US, 2020–2021 (by value and by number)
Figure 72: HHS Information Technology (IT) Strategic Plan, US, 2017–2020
Figure 73: Federal Health IT Strategic Plan Objectives, US, 2020–2025
Figure 74: Deal Value ($B), HealthTech, US, 2019–2020
Figure 75: Deal Count (Number of deals), HealthTech, US, 2019–2020
Figure 76: Proposed Key Components of a Future Pre-Cert Program, US, 2020
Figure 77: Primary Actions, Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan, US, 2021
Figure 78: Overview of Healthcare System, US, 2020
Figure 79: Types of Health Insurance, US, 2020
Figure 80: Medicare Plan Types, US, 2020
Figure 81: Medicare Part D Donut Hole, US, 2020
Figure 82: Part D Percentage Coverage, US, 2015–2020
Figure 83: Features of Medicare and Medicaid, US, 2020
Figure 84: CHIP Timeline, US, 1997–2017
Figure 85: VA Priority Groups, US, 2020
Figure 86: Private Health Insurance Contribution (%), US, 2019
Figure 87: Managed Care Plans, US, 2020
Figure 88: Health Insurance Coverage by Type (% of total population), US, 2019
Figure 89: Out-of-Pocket Spending ($ per capita), US, 2012–2019
Figure 90: Out-of-Pocket Expenditure by Consumption, US, 2018
Figure 91: Prescription Drug Consumer Price Index (CPI) (% change), US, 2010–2020
Figure 92: Pricing at Different Supply Chain Levels, US, 2018
Figure 93: Price Transparency Initiative Timeline, US, 2021–2024
Figure 94: CMS Actions to Promote Price Transparency, US, 2021
Figure 95: FDA, Organization Chart, 2020
Figure 96: Investigational New Drug Application Procedure, US, 2020
Figure 97: New Drug Application Procedure, US, 2020
Figure 98: Abbreviated New Drug Application Procedure, US, 2020
Figure 99: Totality of Evidence Biosimilars, US, 2020
Figure 100: Medical Device Approval Process, US, 2020
Figure 101: Patent Approval Process, US, 2020
Figure 102: Trademark Approval Process, US, 2020
Figure 103: Clinical Trial Approval Process, US, 2020
Figure 104: Pharmaceutical Clinical Trials Count by Trial Status, US, 2019–2021
Figure 105: Pharmaceutical Clinical Trials Count by Phase, US, 2019–2021
Figure 106: Pharmaceutical Clinical Trials Count by Indication, US, 2019–2021
Figure 107: Top Five Pharmaceutical Clinical Trials Sponsors by Count, US, 2019–2021
Figure 108: Medical Devices Clinical Trials Count by Trial Status, US, 2019–2021
Figure 109: Medical Devices Clinical Trials Count by Device Category, US, 2019–2021
Figure 110: Medical Devices Clinical Trials Count by Indication, US, 2019–2021
Figure 111: Top Five Medical Devices Clinical Trials Sponsors by Count, US, 2019–2021
Figure 112: Development of Healthy People 2030, US, 2020
Figure 113: Social Determinants of Health – Healthy People 2030, US, 2020
Figure 114: Opioid Crisis Timeline, US, 1995–2020
Figure 115: Opioid Crisis Five-Point Strategy, US, 2017
Figure 116: Number of Hospitals, US, 2010–2018
Figure 117: Number of Diagnostic Equipment Units (per million population), US, 2012–2019
Figure 118: Number of Hospital Beds (per 1,000 population), US, 2011–2018
Figure 119: Number of Acute Care Beds (per 1,000 population), US, 2011–2018
Figure 120: Number of Psychiatric Care Beds (per 1,000 population), US, 2011–2018
Figure 121: Life Expectancy at Birth (years), US, 2010–2018
Figure 122: Immunization Rate (% of children immunized), US, 2010–2017
Figure 123: PM2.5 (µg per m3), US, 2010–2019
Figure 124: CO2 Emissions (Mt CO2), US, 2010–2019
Figure 125: Physicians (per 1,000 population), US, 2010–2018
Figure 126: Nurses (per 1,000 population), US, 2010–2018
Figure 127: Dentists (per 1,000 population), US, 2010–2019
Figure 128: Pharmacists (per 1,000 population), US, 2010–2018
Figure 129: Major Causes of Mortality (number of deaths per 100,000 population), US, 2019
Figure 130: Major Causes of Male Mortality (number of deaths per 100,000 population) US, 2019
Figure 131: Major Causes of Female Mortality (number of deaths per 100,000 population) US, 2019
Figure 132: Disability-Adjusted Life Years by Major Disease (DALYS per 100,000 population), US, 2019
Figure 133: Healthcare Expenditure as Percentage of GDP (%), US, 2010–2019
Figure 134: Healthcare Spending (government vs. private), US, 2010–2019
Figure 135: Healthcare Expenditure Components by Function (% of total health expenditure), US, 2018
Figure 136: Pharmaceutical Spending ($ per capita), US, 2010–2018
Figure 137: Opportunities and Challenges